戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 ) for eflornithine-sulindac as compared with eflornithine.
2 signed in a 1:1:1 ratio to receive 750 mg of eflornithine, 150 mg of sulindac, or both once daily for
3                            Patients received eflornithine (2.8 g/m(2) orally, every 8 hours [2 weeks
4                                              Eflornithine, alone or combined with nifurtimox, is bein
5 T. brucei, thereby decreasing sensitivity to eflornithine and increasing sensitivity to suramin.
6  significantly lower with the combination of eflornithine and sulindac than with either drug alone.
7 he efficacy and safety of the combination of eflornithine and sulindac, as compared with either drug
8 icacy and safety of combination therapy with eflornithine and sulindac, as compared with either drug
9                              The addition of eflornithine caused no change in the accumulation of nif
10 t the BBB, but also the impact of nifurtimox-eflornithine combination therapy (NECT) and other anti-H
11         The recent development of nifurtimox-eflornithine combination therapy (NECT) has brought new
12  Health Organization approved the nifurtimox-eflornithine combination therapy for the treatment of hu
13                                   Nifurtimox-eflornithine combination therapy remains recommended for
14 reatment options, pentamidine and nifurtimox-eflornithine combination therapy, have been expanded to
15                                              Eflornithine combined with nifurtimox is the first-line
16 ornithine decarboxylase (ODC) using low-dose eflornithine (DFMO, CPP-1X), combined with maximal PA ex
17                      The "resurrection drug" eflornithine (difluoromethylornithine), which is used cl
18 e to chemoprevention with the ODC inhibitor, eflornithine (difluoromethylornithine; DFMO).
19 he sulindac group, and 23 of 57 (40%) in the eflornithine group, with a hazard ratio of 0.71 (95% con
20 e biosynthesis by the anti-trypanosomal drug Eflornithine impairs the ability of the cytosol and mito
21 ODC), an important target of the trypanocide eflornithine, is mediated by TbCul-A/CUL-1.
22  Food and Drug Administration (FDA) approved eflornithine (IWILFIN, US WorldMeds) to reduce the risk
23 were related to reversible myelosuppression (eflornithine + lomustine 42% v lomustine monotherapy 29%
24  there was no difference in survival between eflornithine + lomustine and lomustine monotherapy (medi
25 cally meaningful improvements were observed; eflornithine + lomustine doubled PFS and improved OS in
26 ly meaningful improvements in median OS with eflornithine + lomustine versus lomustine monotherapy (3
27                                              Eflornithine normalized polyamine levels without disrupt
28                                              Eflornithine's manageable safety profile and strong nonc
29  = 0.29) and 0.66 (95% CI, 0.36 to 1.24) for eflornithine-sulindac as compared with eflornithine.
30  confidence interval [CI], 0.39 to 1.32) for eflornithine-sulindac as compared with sulindac (P = 0.2
31 n occurred in 18 of 56 patients (32%) in the eflornithine-sulindac group, 22 of 58 (38%) in the sulin
32 rom previous studies and metabolic profiles, eflornithine was identified as potentially beneficial wi
33 : difluoromethylornithine (DFMO; also called eflornithine), which is a suicide inhibitor of ornithine
34 s the target of the WHO "essential medicine" eflornithine, which is antagonistic to another anti-HAT